GB9105992D0
(en)
*
|
1991-03-21 |
1991-05-08 |
Smithkline Beecham Biolog |
Vaccine
|
US6620414B2
(en)
*
|
1992-03-27 |
2003-09-16 |
Smithkline Beecham Biologicals (S.A.) |
Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
|
EP2289548A3
(fr)
*
|
1992-05-23 |
2012-08-08 |
GlaxoSmithKline Biologicals S.A. |
Vaccins combinés contenant des antigènes de surface du virus de l'hepatite B et d'autres antigènes
|
JP3734263B2
(ja)
*
|
1993-05-25 |
2006-01-11 |
ワイス・ホールディングズ・コーポレイション |
呼吸器シンシチウムウイルスに対するワクチンのためのアジュバント
|
GB9326253D0
(en)
|
1993-12-23 |
1994-02-23 |
Smithkline Beecham Biolog |
Vaccines
|
GB9503863D0
(en)
*
|
1995-02-25 |
1995-04-19 |
Smithkline Beecham Biolog |
Vaccine compositions
|
US6488934B1
(en)
|
1995-02-25 |
2002-12-03 |
Smithkline Beecham Biologicals S.A. |
Hepatitis B vaccine
|
UA56132C2
(uk)
*
|
1995-04-25 |
2003-05-15 |
Смітклайн Бічем Байолоджікалс С.А. |
Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
|
US6696065B1
(en)
*
|
1995-05-04 |
2004-02-24 |
Aventis Pastuer Limited |
Acellular pertussis vaccines and methods of preparation thereof
|
DE69737413T2
(de)
|
1996-01-04 |
2007-10-31 |
Novartis Vaccines and Diagnostics, Inc., Emeryville |
Bakterioferritin aus helicobacter pylori
|
US20060024301A1
(en)
*
|
1997-02-25 |
2006-02-02 |
Corixa Corporation |
Prostate-specific polypeptides and fusion polypeptides thereof
|
US20060269532A1
(en)
*
|
1997-02-25 |
2006-11-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20030185830A1
(en)
*
|
1997-02-25 |
2003-10-02 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US7517952B1
(en)
*
|
1997-02-25 |
2009-04-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US6491919B2
(en)
|
1997-04-01 |
2002-12-10 |
Corixa Corporation |
Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
|
JP5019494B2
(ja)
*
|
1997-04-01 |
2012-09-05 |
コリクサ コーポレーション |
モノホスホリルリピドaの水性免疫アジュバント組成物
|
GB9706957D0
(en)
*
|
1997-04-05 |
1997-05-21 |
Smithkline Beecham Plc |
Formulation
|
US6368604B1
(en)
*
|
1997-09-26 |
2002-04-09 |
University Of Maryland Biotechnology Institute |
Non-pyrogenic derivatives of lipid A
|
GB9724531D0
(en)
|
1997-11-19 |
1998-01-21 |
Smithkline Biolog |
Novel compounds
|
US20080050367A1
(en)
|
1998-04-07 |
2008-02-28 |
Guriq Basi |
Humanized antibodies that recognize beta amyloid peptide
|
US7964192B1
(en)
*
|
1997-12-02 |
2011-06-21 |
Janssen Alzheimer Immunotherapy |
Prevention and treatment of amyloidgenic disease
|
US6913745B1
(en)
|
1997-12-02 |
2005-07-05 |
Neuralab Limited |
Passive immunization of Alzheimer's disease
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
US7588766B1
(en)
|
2000-05-26 |
2009-09-15 |
Elan Pharma International Limited |
Treatment of amyloidogenic disease
|
US6787523B1
(en)
|
1997-12-02 |
2004-09-07 |
Neuralab Limited |
Prevention and treatment of amyloidogenic disease
|
US6750324B1
(en)
|
1997-12-02 |
2004-06-15 |
Neuralab Limited |
Humanized and chimeric N-terminal amyloid beta-antibodies
|
US7790856B2
(en)
|
1998-04-07 |
2010-09-07 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
US7179892B2
(en)
*
|
2000-12-06 |
2007-02-20 |
Neuralab Limited |
Humanized antibodies that recognize beta amyloid peptide
|
US6923964B1
(en)
|
1997-12-02 |
2005-08-02 |
Neuralab Limited |
Active immunization of AScr for prion disorders
|
TWI239847B
(en)
*
|
1997-12-02 |
2005-09-21 |
Elan Pharm Inc |
N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
|
US6761888B1
(en)
*
|
2000-05-26 |
2004-07-13 |
Neuralab Limited |
Passive immunization treatment of Alzheimer's disease
|
DE19803453A1
(de)
*
|
1998-01-30 |
1999-08-12 |
Boehringer Ingelheim Int |
Vakzine
|
GB9808866D0
(en)
|
1998-04-24 |
1998-06-24 |
Smithkline Beecham Biolog |
Novel compounds
|
US20030147882A1
(en)
*
|
1998-05-21 |
2003-08-07 |
Alan Solomon |
Methods for amyloid removal using anti-amyloid antibodies
|
WO1999061048A1
(fr)
*
|
1998-05-22 |
1999-12-02 |
Smithkline Beecham Corporation |
PROTECTION CORRELATIVE FAISANT APPEL A DES TITRES D'ANTICORPS OspA
|
US6306404B1
(en)
|
1998-07-14 |
2001-10-23 |
American Cyanamid Company |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
AU763770B2
(en)
*
|
1998-07-14 |
2003-07-31 |
Wyeth Holdings Corporation |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
US20040213806A1
(en)
*
|
1998-08-28 |
2004-10-28 |
Smithkline Beecham Biologicals, S.A. |
Salmonella typhi vaccine compositions
|
GB9819898D0
(en)
*
|
1998-09-11 |
1998-11-04 |
Smithkline Beecham Plc |
New vaccine and method of use
|
US6692752B1
(en)
|
1999-09-08 |
2004-02-17 |
Smithkline Beecham Biologicals S.A. |
Methods of treating human females susceptible to HSV infection
|
GB9820525D0
(en)
*
|
1998-09-21 |
1998-11-11 |
Allergy Therapeutics Ltd |
Formulation
|
GB9822714D0
(en)
|
1998-10-16 |
1998-12-09 |
Smithkline Beecham Sa |
Vaccines
|
US7357936B1
(en)
*
|
1998-10-16 |
2008-04-15 |
Smithkline Beecham Biologicals, Sa |
Adjuvant systems and vaccines
|
ATE527360T1
(de)
|
1998-12-08 |
2011-10-15 |
Glaxosmithkline Biolog Sa |
Neue verbindungen abgeleitet von neisseria meningitidis
|
DK1163343T3
(da)
|
1999-03-12 |
2010-04-19 |
Glaxosmithkline Biolog Sa |
Neisseria meningitidis antigene polypeptider, tilsvarende polynukleotider og beskyttende antistoffer
|
GB9909077D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Biolog |
Novel compositions
|
MY125387A
(en)
|
1999-03-19 |
2006-07-31 |
Smithkline Beecham Biologicals S A |
Vaccine
|
IL145982A0
(en)
|
1999-04-19 |
2002-07-25 |
Smithkline Beecham Biolog |
Vaccines
|
US6558670B1
(en)
|
1999-04-19 |
2003-05-06 |
Smithkline Beechman Biologicals S.A. |
Vaccine adjuvants
|
GEP20053446B
(en)
*
|
1999-05-13 |
2005-02-25 |
Wyeth Corp |
Adjuvant Combination Formulations
|
US6787637B1
(en)
|
1999-05-28 |
2004-09-07 |
Neuralab Limited |
N-Terminal amyloid-β antibodies
|
UA81216C2
(en)
*
|
1999-06-01 |
2007-12-25 |
|
Prevention and treatment of amyloid disease
|
US6635261B2
(en)
|
1999-07-13 |
2003-10-21 |
Wyeth Holdings Corporation |
Adjuvant and vaccine compositions containing monophosphoryl lipid A
|
GB9921146D0
(en)
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB9921147D0
(en)
*
|
1999-09-07 |
1999-11-10 |
Smithkline Beecham Biolog |
Novel composition
|
GB9923176D0
(en)
|
1999-09-30 |
1999-12-01 |
Smithkline Beecham Biolog |
Novel composition
|
US8017590B1
(en)
|
1999-10-22 |
2011-09-13 |
Sanofi Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
EP1104767A1
(fr)
|
1999-11-30 |
2001-06-06 |
Stichting Dienst Landbouwkundig Onderzoek |
Dérivés de mono- et disaccharides contenant esters d'acides gras et esters de sulfate
|
GB0000891D0
(en)
*
|
2000-01-14 |
2000-03-08 |
Allergy Therapeutics Ltd |
Formulation
|
EP1282702B1
(fr)
|
2000-05-10 |
2006-11-29 |
Sanofi Pasteur Limited |
Polypeptides immunogeniques codes par des minigenes mage et leurs utilisations
|
US6821519B2
(en)
*
|
2000-06-29 |
2004-11-23 |
Corixa Corporation |
Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
CA2436107C
(fr)
*
|
2000-10-06 |
2012-05-22 |
H. Henrich Paradies |
Cybermedicament utilise comme autovaccins avec effets d'immunoregulation
|
PL211151B1
(pl)
|
2000-10-18 |
2012-04-30 |
Glaxosmithkline Biolog Sa |
Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
|
EP2284183A1
(fr)
|
2000-10-27 |
2011-02-16 |
Novartis Vaccines and Diagnostics S.r.l. |
Acides nucléiques et protéines dérivés des groupes de streptocoques A et B
|
US7048931B1
(en)
*
|
2000-11-09 |
2006-05-23 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
EE200300172A
(et)
*
|
2000-11-10 |
2003-06-16 |
Wyeth Holdings Corporation |
Antigeenne kompositsioon ja adjuvantsegu
|
US7700751B2
(en)
|
2000-12-06 |
2010-04-20 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize β-amyloid peptide
|
PE20020574A1
(es)
|
2000-12-06 |
2002-07-02 |
Wyeth Corp |
Anticuerpos humanizados que reconocen el peptido amiloideo beta
|
WO2002046477A2
(fr)
|
2000-12-07 |
2002-06-13 |
Chiron Corporation |
Retrovirus endogenes regules positivement dans le cancer de la prostate
|
AU2002254901A1
(en)
|
2001-02-23 |
2002-10-03 |
Smithkline Beecham Biologicals S.A. |
Influenza vaccine formulations for intradermal delivery
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
US8481043B2
(en)
|
2001-06-22 |
2013-07-09 |
Cpex Pharmaceuticals, Inc. |
Nasal immunization
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
US7361352B2
(en)
|
2001-08-15 |
2008-04-22 |
Acambis, Inc. |
Influenza immunogen and vaccine
|
AR045702A1
(es)
|
2001-10-03 |
2005-11-09 |
Chiron Corp |
Composiciones de adyuvantes.
|
ES2607431T3
(es)
|
2002-02-20 |
2017-03-31 |
Glaxosmithkline Biologicals Sa |
Micropartículas con moléculas que contienen polipéptidos adsorbidos
|
US7351413B2
(en)
|
2002-02-21 |
2008-04-01 |
Lorantis, Limited |
Stabilized HBc chimer particles as immunogens for chronic hepatitis
|
MY139983A
(en)
|
2002-03-12 |
2009-11-30 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
GB0206360D0
(en)
|
2002-03-18 |
2002-05-01 |
Glaxosmithkline Biolog Sa |
Viral antigens
|
AU2003276679A1
(en)
|
2002-06-13 |
2003-12-31 |
Chiron Corporation |
Vectors for expression of hml-2 polypeptides
|
JP4697706B2
(ja)
|
2002-10-11 |
2011-06-08 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
|
WO2004037189A2
(fr)
|
2002-10-23 |
2004-05-06 |
Glaxosmithkline Biologicals S.A. |
Methodes de vaccination contre le paludisme
|
US7858098B2
(en)
|
2002-12-20 |
2010-12-28 |
Glaxosmithkline Biologicals, S.A. |
Vaccine
|
CA3042073C
(fr)
|
2003-01-30 |
2022-09-13 |
Novartis Vaccines And Diagnostics S.R.L. |
Vaccins injectables contre les multiples serogroupes du meningocoque
|
TWI374893B
(en)
|
2003-05-30 |
2012-10-21 |
Janssen Alzheimer Immunotherap |
Humanized antibodies that recognize beta amyloid peptide
|
CA2528007C
(fr)
|
2003-06-02 |
2012-03-27 |
Chiron Corporation |
Compositions immunogenes basees sur des microparticules comprenant des antigenes contenant de l'anatoxine adsorbee et des polysaccharides
|
GB0321615D0
(en)
|
2003-09-15 |
2003-10-15 |
Glaxo Group Ltd |
Improvements in vaccination
|
JP4738339B2
(ja)
|
2003-10-02 |
2011-08-03 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル |
複数の髄膜炎菌血清群についての液体ワクチン
|
ATE474595T1
(de)
|
2003-10-02 |
2010-08-15 |
Glaxosmithkline Biolog Sa |
B. pertussis antigene und ihre verwendung bei der vakzinierung
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
EP1722815A1
(fr)
|
2004-03-09 |
2006-11-22 |
Chiron Corporation |
Vaccins antigrippaux
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
EP1740217B1
(fr)
|
2004-04-30 |
2011-06-15 |
Novartis Vaccines and Diagnostics S.r.l. |
Integration d'une vaccination conjuguee antimeningococcique
|
GB0500787D0
(en)
|
2005-01-14 |
2005-02-23 |
Chiron Srl |
Integration of meningococcal conjugate vaccination
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
JP4896021B2
(ja)
|
2004-05-21 |
2012-03-14 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
呼吸器系病原体ワクチンのためのアルファウイルスベクター
|
ATE491467T1
(de)
|
2004-05-28 |
2011-01-15 |
Glaxosmithkline Biolog Sa |
Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
|
US7758866B2
(en)
|
2004-06-16 |
2010-07-20 |
Glaxosmithkline Biologicals, S.A. |
Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
|
US20090317420A1
(en)
|
2004-07-29 |
2009-12-24 |
Chiron Corporation |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0417494D0
(en)
|
2004-08-05 |
2004-09-08 |
Glaxosmithkline Biolog Sa |
Vaccine
|
EP2305294B1
(fr)
|
2004-09-22 |
2015-04-01 |
GlaxoSmithKline Biologicals SA |
Composition immunogène pour la vaccination contre des staphylocoques
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
EP2923711A1
(fr)
*
|
2004-11-03 |
2015-09-30 |
Novartis Vaccines and Diagnostics, Inc. |
Vaccin contre la grippe
|
US7625560B2
(en)
*
|
2004-12-15 |
2009-12-01 |
Janssen Alzheimer Immunotherapy |
Humanized antibodies that recognize beta amyloid peptide
|
CA2590337C
(fr)
|
2004-12-15 |
2017-07-11 |
Neuralab Limited |
Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
|
CN101107007B
(zh)
|
2005-01-27 |
2011-08-17 |
奥克兰儿童医院及研究中心 |
对脑膜炎奈瑟球菌所致疾病具有广谱保护作用的gna1870囊泡疫苗
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
BRPI0608430A2
(pt)
*
|
2005-02-16 |
2009-12-29 |
Novartis Vaccines & Diagnostics Inc |
composição adjuvante, processo para preparar a mesma e uso da mesma
|
GB0503337D0
(en)
|
2005-02-17 |
2005-03-23 |
Glaxosmithkline Biolog Sa |
Compositions
|
NZ580974A
(en)
|
2005-02-18 |
2011-05-27 |
Novartis Vaccines & Diagnostic |
Immunogens from uropathogenic escherichia coli
|
NZ561042A
(en)
|
2005-02-18 |
2011-03-31 |
Novartis Vaccines & Diagnostic |
Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli - SEQ ID: 7052
|
GB0504436D0
(en)
|
2005-03-03 |
2005-04-06 |
Glaxosmithkline Biolog Sa |
Vaccine
|
WO2006100110A1
(fr)
|
2005-03-23 |
2006-09-28 |
Glaxosmithkline Biologicals S.A. |
Nouvelle composition
|
SG175456A1
(en)
|
2005-04-18 |
2011-11-28 |
Novartis Vaccines & Diagnostic |
Expressing hepatitis b virus surface antigen for vaccine preparation
|
CN101273055B
(zh)
|
2005-04-29 |
2016-03-16 |
葛兰素史密丝克莱恩生物有限公司 |
用于预防或治疗结核分枝杆菌感染的新方法
|
GB0513421D0
(en)
|
2005-06-30 |
2005-08-03 |
Glaxosmithkline Biolog Sa |
Vaccines
|
CN101355960A
(zh)
|
2005-10-18 |
2009-01-28 |
诺华疫苗和诊断公司 |
使用α病毒复制子颗粒进行粘膜和全身免疫
|
US11707520B2
(en)
|
2005-11-03 |
2023-07-25 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
US10842867B2
(en)
|
2005-11-04 |
2020-11-24 |
Seqirus UK Limited |
Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
|
AU2006310163B2
(en)
|
2005-11-04 |
2011-09-15 |
Seqirus UK Limited |
Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
|
KR20080069232A
(ko)
*
|
2005-11-04 |
2008-07-25 |
노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. |
스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼
|
NZ567979A
(en)
|
2005-11-04 |
2012-02-24 |
Novartis Vaccines & Diagnostic |
Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
|
WO2007052058A1
(fr)
|
2005-11-04 |
2007-05-10 |
Novartis Vaccines And Diagnostics Srl |
Vaccins influenza comprenant des combinaisons d'adjuvants particulaires et d'immunopotentiateurs
|
GB0522765D0
(en)
*
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
CA2630220C
(fr)
|
2005-11-22 |
2020-10-13 |
Doris Coit |
Antigenes de norovirus et de sapovirus
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
KR101515078B1
(ko)
|
2005-12-22 |
2015-04-24 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
ES2809167T3
(es)
|
2006-01-17 |
2021-03-03 |
Forsgren Arne |
Una novedosa proteína de Haemophilus influenzae expuesta en la superficie (proteína E; pE)
|
BRPI0707300B8
(pt)
|
2006-01-27 |
2021-05-25 |
Novartis Ag |
vacina contra vírion influenza dividido ou antígeno de superfície purificado e método para a preparação de uma composição imunogênica
|
US8063063B2
(en)
|
2006-03-23 |
2011-11-22 |
Novartis Ag |
Immunopotentiating compounds
|
CA2646539A1
(fr)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Composes d'imidazoquinoxaline utilises en tant qu'immunomodulateurs
|
AU2007231027B2
(en)
|
2006-03-24 |
2013-10-03 |
Novartis Influenza Vaccines Marburg Gmbh |
Storage of influenza vaccines without refrigeration
|
EA020459B1
(ru)
|
2006-03-30 |
2014-11-28 |
Глаксосмитклайн Байолоджикалс С.А. |
Иммуногенная композиция
|
US9839685B2
(en)
|
2006-04-13 |
2017-12-12 |
The Regents Of The University Of Michigan |
Methods of inducing human immunodeficiency virus-specific immune responses in a host comprising nasally administering compositions comprising a naonemulsion and recombinant GP120 immunogen
|
US10138279B2
(en)
|
2006-04-13 |
2018-11-27 |
Regents Of The University Of Michigan |
Compositions and methods for Bacillus anthracis vaccination
|
WO2009017467A1
(fr)
|
2007-07-27 |
2009-02-05 |
Elan Pharma International Limited |
Traitement de maladies amyloïdogéniques
|
US8784810B2
(en)
|
2006-04-18 |
2014-07-22 |
Janssen Alzheimer Immunotherapy |
Treatment of amyloidogenic diseases
|
EP2035035A2
(fr)
|
2006-06-09 |
2009-03-18 |
Novartis AG |
Compositions immunogenes pour streptococcus agalactiae
|
PL2422810T3
(pl)
|
2006-07-17 |
2015-03-31 |
Glaxosmithkline Biologicals Sa |
Szczepionka przeciw grypie
|
BRPI0715581A2
(pt)
|
2006-07-18 |
2013-04-24 |
Glaxosmithkline Biolog Sa |
proteÍna de fusço hÍbrida imunogÊnica, composiÇço, uso de uma proteÍna ou uma partÍcula, mÉtodo para tratar um paciente suscetÍvel À infecÇço por plasmàdio, sequÊncia de nucleotÍdeo, hospedeiro, e, processo para a produÇço de proteÍna
|
GB0614460D0
(en)
|
2006-07-20 |
2006-08-30 |
Novartis Ag |
Vaccines
|
EP2040744B1
(fr)
|
2006-07-25 |
2016-03-09 |
The Secretary of State for Defence |
Souche de vaccin vivant
|
EP2586790A3
(fr)
|
2006-08-16 |
2013-08-14 |
Novartis AG |
Immunogènes d'Escherischia coli pathogènes des voies urinaires
|
MX2009002408A
(es)
|
2006-09-11 |
2009-03-20 |
Novartis Ag |
Elaboracion de vacunas para el virus de la influenza sin utilizar huevos.
|
AU2007354917B2
(en)
|
2006-09-26 |
2013-06-06 |
Access To Advanced Health Institute |
Vaccine composition containing synthetic adjuvant
|
US20090181078A1
(en)
|
2006-09-26 |
2009-07-16 |
Infectious Disease Research Institute |
Vaccine composition containing synthetic adjuvant
|
CA2664157C
(fr)
|
2006-09-29 |
2015-12-01 |
Ligocyte Pharmaceuticals, Inc. |
Formulations de vaccin contre un norovirus
|
EP2433648A3
(fr)
|
2006-10-12 |
2012-04-04 |
GlaxoSmithKline Biologicals S.A. |
Vaccin comprenant une émulsion adjuvante huile en l'eau
|
PT2086582E
(pt)
|
2006-10-12 |
2013-01-25 |
Glaxosmithkline Biolog Sa |
Vacina compreendendo uma emulsão adjuvante óleo em água
|
EP2121011B1
(fr)
|
2006-12-06 |
2014-05-21 |
Novartis AG |
Vaccins comprenant un antigène issu de quatre souches du virus grippal
|
LT2137210T
(lt)
|
2007-03-02 |
2016-12-27 |
Glaxosmithkline Biologicals Sa |
Naujas būdas ir kompozicijos
|
US8003097B2
(en)
|
2007-04-18 |
2011-08-23 |
Janssen Alzheimer Immunotherapy |
Treatment of cerebral amyloid angiopathy
|
US9452209B2
(en)
|
2007-04-20 |
2016-09-27 |
Glaxosmithkline Biologicals Sa |
Influenza vaccine
|
ES2552366T3
(es)
|
2007-06-26 |
2015-11-27 |
Glaxosmithkline Biologicals S.A. |
Vacuna que comprende conjugados de polisacárido capsular de Streptococcus pneumoniae
|
PT2185191E
(pt)
|
2007-06-27 |
2012-11-27 |
Novartis Ag |
Vacinas contra a gripe com baixo teor de aditivos
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
WO2009016639A2
(fr)
*
|
2007-08-02 |
2009-02-05 |
Biondvax Pharmaceuticals Ltd. |
Vaccins contre la grippe à multiples épitopes multimères
|
CA2695421A1
(fr)
|
2007-08-03 |
2009-02-12 |
President And Fellows Of Harvard College |
Antigenes chlamydiens
|
KR20100068390A
(ko)
|
2007-08-13 |
2010-06-23 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
백신
|
MX2010002773A
(es)
|
2007-09-12 |
2010-03-31 |
Novartis Ag |
Antigenos mutantes de gas57 y anticuerpos de gas57.
|
JO3076B1
(ar)
|
2007-10-17 |
2017-03-15 |
Janssen Alzheimer Immunotherap |
نظم العلاج المناعي المعتمد على حالة apoe
|
GB0810305D0
(en)
|
2008-06-05 |
2008-07-09 |
Novartis Ag |
Influenza vaccination
|
EP2227250A4
(fr)
|
2007-12-03 |
2011-07-06 |
Harvard College |
Antigènes de chlamydia
|
ES2664753T3
(es)
|
2007-12-07 |
2018-04-23 |
Glaxosmithkline Biologicals Sa |
Composiciones de inducción de respuestas inmunes
|
AU2008352942B2
(en)
|
2007-12-19 |
2013-09-12 |
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. |
Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
CN104292312A
(zh)
|
2007-12-21 |
2015-01-21 |
诺华股份有限公司 |
链球菌溶血素o的突变形式
|
SI2222710T1
(sl)
|
2007-12-24 |
2016-11-30 |
Id Biomedical Corporation Of Quebec |
Rekombinatni RSV antigeni
|
US9579372B2
(en)
|
2008-02-21 |
2017-02-28 |
Glaxosmithkline Biologicals Sa |
Meningococcal fHBP polypeptides
|
US8506966B2
(en)
*
|
2008-02-22 |
2013-08-13 |
Novartis Ag |
Adjuvanted influenza vaccines for pediatric use
|
AU2009223613B2
(en)
|
2008-03-10 |
2014-09-25 |
Children's Hospital & Research Center At Oakland |
Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
|
CA2718430A1
(fr)
|
2008-03-18 |
2009-09-24 |
Novartis Ag |
Ameliorations dans la preparation des antigenes pour le vaccin contre le virus de la grippe
|
PT2271360E
(pt)
|
2008-04-16 |
2015-12-07 |
Glaxosmithkline Biolog Sa |
Vacina
|
WO2009143524A2
(fr)
|
2008-05-23 |
2009-11-26 |
The Regents Of The University Of Michigan |
Vaccins à nanoémulsion
|
CA2731194A1
(fr)
*
|
2008-07-18 |
2010-01-21 |
Id Biomedical Corporation Of Quebec |
Antigenes polypeptidiques chimeriques du virus respiratoire syncytial
|
GB0815872D0
(en)
|
2008-09-01 |
2008-10-08 |
Pasteur Institut |
Novel method and compositions
|
CN102223876A
(zh)
|
2008-09-26 |
2011-10-19 |
纳米生物公司 |
纳米乳剂治疗性组合物及其使用方法
|
US9067981B1
(en)
|
2008-10-30 |
2015-06-30 |
Janssen Sciences Ireland Uc |
Hybrid amyloid-beta antibodies
|
EP2376089B1
(fr)
|
2008-11-17 |
2018-03-14 |
The Regents of the University of Michigan |
Compositions de vaccins contre le cancer et leurs méthodes d' utilisation
|
BRPI0922132A2
(pt)
|
2008-12-03 |
2018-10-23 |
Protea Vaccine Tech Ltd |
fragmentos glutamil trna sintetase (gts).
|
AU2009325950B2
(en)
|
2008-12-09 |
2013-03-07 |
Pfizer Vaccines Llc |
IgE CH3 peptide vaccine
|
WO2010079081A1
(fr)
|
2009-01-07 |
2010-07-15 |
Glaxosmithkline Biologicals S.A. |
Procédés de récupération d'un virus ou d'un antigène viral produit par culture cellulaire
|
NZ594029A
(en)
|
2009-01-12 |
2014-01-31 |
Novartis Ag |
Cna_b domain antigens in vaccines against gram positive bacteria
|
GB0901423D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
GB0901411D0
(en)
|
2009-01-29 |
2009-03-11 |
Secr Defence |
Treatment
|
US20110293660A1
(en)
|
2009-02-06 |
2011-12-01 |
Bruno Rene Andre |
Novel method
|
EA201500910A1
(ru)
|
2009-02-10 |
2016-04-29 |
Новартис Аг |
Вакцины против гриппа со сниженным количеством сквалена
|
US9265821B2
(en)
|
2009-02-17 |
2016-02-23 |
Glaxosmithkline Biologicals Sa |
Inactivated dengue virus vaccine with aluminium-free adjuvant
|
DK2403507T3
(en)
|
2009-03-05 |
2018-06-06 |
Jenny Colleen Mccloskey |
TREATMENT OF INFECTION
|
JP2012519482A
(ja)
|
2009-03-06 |
2012-08-30 |
ノバルティス アーゲー |
クラミジア抗原
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
DK2510947T3
(en)
|
2009-04-14 |
2016-03-21 |
Glaxosmithkline Biolog Sa |
Compositions for Immunization against Staphylococcus aureus.
|
WO2010125480A1
(fr)
|
2009-04-30 |
2010-11-04 |
Coley Pharmaceutical Group, Inc. |
Vaccin anti-pneumococcique et ses utilisations
|
CA2764374C
(fr)
|
2009-06-05 |
2019-11-19 |
Infectious Disease Research Institute |
Adjuvants lipidiques synthetiques a base de glucopyranosyle
|
GB0910046D0
(en)
*
|
2009-06-10 |
2009-07-22 |
Glaxosmithkline Biolog Sa |
Novel compositions
|
CN102802665B
(zh)
|
2009-06-15 |
2015-11-25 |
新加坡国立大学 |
流感疫苗、组合物及使用方法
|
EP2442827B1
(fr)
|
2009-06-16 |
2016-01-06 |
The Regents of the University of Michigan |
Vaccins en nano-émulsion
|
MX2012000036A
(es)
|
2009-06-24 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
WO2010149745A1
(fr)
|
2009-06-24 |
2010-12-29 |
Glaxosmithkline Biologicals S.A. |
Antigènes recombinants du vrs
|
EP2451833B1
(fr)
|
2009-07-07 |
2018-01-17 |
GlaxoSmithKline Biologicals SA |
Immunogènes d' escherichia coli conservés
|
ES2563730T3
(es)
|
2009-07-15 |
2016-03-16 |
Glaxosmithkline Biologicals S.A. |
Composiciones de proteína RSV F y procedimientos de fabricación de las mismas
|
DK2464658T3
(en)
|
2009-07-16 |
2014-12-15 |
Novartis Ag |
Detoxified escherichia coli immunogens
|
RU2518291C2
(ru)
|
2009-07-30 |
2014-06-10 |
Пфайзер Вэксинс ЭлЭлСи |
Антигенные tau-пептиды и их применения
|
GB0913680D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
US20110076300A1
(en)
|
2009-08-27 |
2011-03-31 |
Mariagrazia Pizza |
Hybrid Polypeptides Including Meningococcal fHBP Sequences
|
CA2771770A1
(fr)
|
2009-09-03 |
2011-03-10 |
Pfizer Vaccines Llc |
Vaccin pcsk9
|
WO2011030218A1
(fr)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Vaccins combinés contre les maladies des voies respiratoires
|
WO2011036220A1
(fr)
|
2009-09-25 |
2011-03-31 |
Glaxosmithkline Biologicals S.A. |
Test d'immunodiffusion pour virus de la grippe
|
GB0917003D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Purification of bacterial vesicles
|
GB0917002D0
(en)
|
2009-09-28 |
2009-11-11 |
Novartis Vaccines Inst For Global Health Srl |
Improved shigella blebs
|
AU2010352695B2
(en)
|
2009-09-30 |
2014-08-21 |
Glaxosmithkline Biologicals S.A. |
Conjugation of Staphylococcus aureus type 5 and type 8 capsular polysaccharides
|
EP2483390A2
(fr)
|
2009-09-30 |
2012-08-08 |
Novartis AG |
Expression de polypeptides fhbp méningococciques
|
GB0918392D0
(en)
|
2009-10-20 |
2009-12-02 |
Novartis Ag |
Diagnostic and therapeutic methods
|
CA2779816A1
(fr)
|
2009-10-27 |
2011-05-05 |
Novartis Ag |
Polypeptides fhbp meningococciques modifies
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
WO2011067758A2
(fr)
|
2009-12-02 |
2011-06-09 |
Protea Vaccine Technologies Ltd. |
Fragments immunogènes et multimères pour protéines de streptococcus pneumoniae
|
DE102009056871A1
(de)
*
|
2009-12-03 |
2011-06-22 |
Novartis AG, 4056 |
Impfstoff-Adjuvantien und verbesserte Verfahren zur Herstellung derselben
|
CA2785585A1
(fr)
|
2009-12-22 |
2011-06-30 |
Celldex Therapeutics, Inc. |
Compositions de vaccin
|
US9173954B2
(en)
|
2009-12-30 |
2015-11-03 |
Glaxosmithkline Biologicals Sa |
Polysaccharide immunogens conjugated to E. coli carrier proteins
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
MX2012011189A
(es)
|
2010-03-26 |
2013-02-07 |
Glaxosmithkline Biolog Sa |
Vacuna contra el virus e inmunodeficiencia humana.
|
BR122021020829B8
(pt)
|
2010-03-30 |
2022-12-27 |
Children´S Hospital & Res Center At Oakland |
Proteína de ligação ao fator h de ocorrência não natural (fhbp), composição, e célula hospedeira de neisseria meningitidis geneticamente modificada
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
EP2556151A1
(fr)
|
2010-04-07 |
2013-02-13 |
Novartis AG |
Procédé de génération de pseudo-particules virales de parvovirus b19
|
CA2796314A1
(fr)
|
2010-04-13 |
2011-10-20 |
Novartis Ag |
Compositions de benzonapthyridine et leurs utilisations
|
BR112012027643A2
(pt)
|
2010-05-03 |
2016-08-16 |
Glaxosmithkline Biolog Sa |
métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica
|
JP2013532008A
(ja)
|
2010-05-28 |
2013-08-15 |
テトリス オンライン インコーポレイテッド |
対話式ハイブリッド非同期コンピュータ・ゲーム・インフラストラクチャ
|
GB201009273D0
(en)
|
2010-06-03 |
2010-07-21 |
Glaxosmithkline Biolog Sa |
Novel vaccine
|
CA2800774A1
(fr)
|
2010-06-07 |
2011-12-15 |
Pfizer Vaccines Llc |
Vaccin peptidique ige ch3
|
EP2576613A1
(fr)
|
2010-06-07 |
2013-04-10 |
Pfizer Inc. |
Peptides her-2 et vaccins
|
GB201009861D0
(en)
|
2010-06-11 |
2010-07-21 |
Novartis Ag |
OMV vaccines
|
US8658603B2
(en)
|
2010-06-16 |
2014-02-25 |
The Regents Of The University Of Michigan |
Compositions and methods for inducing an immune response
|
MX2013000163A
(es)
|
2010-07-06 |
2013-03-05 |
Novartis Ag |
Metodos y composiciones inmunogenicas derivadas de norovirus.
|
US9192661B2
(en)
|
2010-07-06 |
2015-11-24 |
Novartis Ag |
Delivery of self-replicating RNA using biodegradable polymer particles
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
US9168292B2
(en)
|
2010-09-27 |
2015-10-27 |
Crucell Holland B.V. |
Heterologous prime boost vaccination regimen against malaria
|
US20130280322A1
(en)
|
2010-09-27 |
2013-10-24 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
AU2011315447A1
(en)
|
2010-10-15 |
2013-05-09 |
Glaxosmithkline Biologicals S.A. |
Cytomegalovirus gB antigen
|
GB201017519D0
(en)
|
2010-10-15 |
2010-12-01 |
Novartis Vaccines Inst For Global Health S R L |
Vaccines
|
FR2966044B1
(fr)
*
|
2010-10-18 |
2012-11-02 |
Sanofi Pasteur |
Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
|
WO2012072769A1
(fr)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Epitopes rrgb de pneumocoque et combinaisons de variantes
|
WO2012072088A1
(fr)
|
2010-12-02 |
2012-06-07 |
Bionor Immuno As |
Conception d'échafaudage peptidique
|
CN103260642B
(zh)
|
2010-12-14 |
2018-03-16 |
葛兰素史密丝克莱恩生物有限公司 |
分枝杆菌抗原组合物
|
EP2655389A2
(fr)
|
2010-12-24 |
2013-10-30 |
Novartis AG |
Composés
|
GB201022007D0
(en)
|
2010-12-24 |
2011-02-02 |
Imp Innovations Ltd |
DNA-sensor
|
MX346475B
(es)
|
2011-01-06 |
2017-03-22 |
Bionor Immuno As |
Peptidos inmunogenicos monomericos y multimericos.
|
DK2667892T3
(da)
|
2011-01-26 |
2019-05-13 |
Glaxosmithkline Biologicals Sa |
RSV-vaccineringsprogram
|
CN103517713A
(zh)
|
2011-02-22 |
2014-01-15 |
彼昂德瓦克斯医药有限公司 |
在改善的季节性和大流行性流感疫苗中的多聚体多表位多肽
|
WO2012131504A1
(fr)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Vaccin à base de pcsk9
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
NZ616304A
(en)
|
2011-04-08 |
2016-01-29 |
Immune Design Corp |
Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
|
TW201302779A
(zh)
|
2011-04-13 |
2013-01-16 |
Glaxosmithkline Biolog Sa |
融合蛋白質及組合疫苗
|
HUE034673T2
(en)
|
2011-05-13 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Pre-fusion Rsv F antigens
|
US20140072622A1
(en)
|
2011-05-17 |
2014-03-13 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
AU2012279154A1
(en)
|
2011-07-01 |
2014-02-20 |
The Regents Of The University Of California |
Herpes virus vaccine and methods of use
|
ES2656050T3
(es)
|
2011-07-06 |
2018-02-22 |
Glaxosmithkline Biologicals Sa |
Composiciones de combinación inmunogénica y usos de las mismas
|
CA2841047A1
(fr)
|
2011-07-06 |
2013-01-10 |
Novartis Ag |
Compositions immunogenes et leurs utilisations
|
US9149541B2
(en)
|
2011-07-08 |
2015-10-06 |
Novartis Ag |
Tyrosine ligation process
|
EP2731621B1
(fr)
|
2011-07-11 |
2017-11-01 |
Takeda Vaccines, Inc. |
Formulations de vaccin parentéral contre un norovirus
|
ES2687129T3
(es)
|
2011-07-25 |
2018-10-23 |
Glaxosmithkline Biologicals Sa |
Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
KR20140066212A
(ko)
|
2011-09-01 |
2014-05-30 |
노파르티스 아게 |
스타필로코쿠스 아우레우스 항원의 보조제 첨가된 조제물
|
US9358284B2
(en)
|
2011-09-14 |
2016-06-07 |
Glaxosmithkline Biologicals Sa |
Methods for making saccharide-protein glycoconjugates
|
PE20141547A1
(es)
|
2011-09-16 |
2014-10-25 |
Ucb Pharma Sa |
Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile
|
GB201116248D0
(en)
|
2011-09-20 |
2011-11-02 |
Glaxosmithkline Biolog Sa |
Liposome production using isopropanol
|
CA2854934A1
(fr)
|
2011-11-07 |
2013-05-16 |
Novartis Ag |
Molecule porteuse comprenant un antigene spr0096 et un antigene spr2021
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
WO2013108272A2
(fr)
|
2012-01-20 |
2013-07-25 |
International Centre For Genetic Engineering And Biotechnology |
Vaccin antipaludique ciblant le stade sanguin
|
US20150030630A1
(en)
|
2012-03-07 |
2015-01-29 |
Novartis Ag |
Adjuvanted formulations of rabies virus immunogens
|
WO2013131983A1
(fr)
|
2012-03-07 |
2013-09-12 |
Novartis Ag |
Formulations contenant un adjuvant d'antigènes de streptococcus pneumoniae
|
EP2822584A1
(fr)
|
2012-03-08 |
2015-01-14 |
Novartis AG |
Vaccins combinés comprenant des agonistes du tlr4
|
RU2014140521A
(ru)
|
2012-03-08 |
2016-04-27 |
Новартис Аг |
Адъювантные составы бустерных вакцин
|
EP2827891A1
(fr)
|
2012-03-18 |
2015-01-28 |
GlaxoSmithKline Biologicals S.A. |
Procédé de vaccination contre le papillomavirus humain
|
ES2702278T3
(es)
|
2012-04-01 |
2019-02-28 |
Technion Res & Dev Foundation |
Péptidos de inductor de metaloproteinasa de matriz extracelular (emmprin) y anticuerpos de unión
|
EP2659907A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659906A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
EP2659908A1
(fr)
|
2012-05-01 |
2013-11-06 |
Affiris AG |
Compositions
|
MX359257B
(es)
|
2012-05-04 |
2018-09-19 |
Pfizer |
Antígenos asociados a próstata y regímenes de inmunoterapia basados en vacuna.
|
SI2850431T1
(en)
|
2012-05-16 |
2018-08-31 |
Immune Design Corp. |
Vaccine against HSV-2
|
ES2820898T3
(es)
|
2012-05-22 |
2021-04-22 |
Glaxosmithkline Biologicals Sa |
Conjugado del serogrupo X de meningococos
|
EP2666785A1
(fr)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Vaccins basés sur la protéine complément C5a
|
NZ702146A
(en)
|
2012-06-06 |
2016-11-25 |
Bionor Immuno As |
Peptides derived from viral proteins for use as immunogens and dosage reactants
|
JP2015522580A
(ja)
|
2012-07-06 |
2015-08-06 |
ノバルティス アーゲー |
免疫学的組成物およびその使用
|
JP2015525794A
(ja)
|
2012-08-06 |
2015-09-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
乳児においてrsv及び百日咳菌に対する免疫応答を惹起するための方法
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
EP2703483A1
(fr)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
Vaccin à base de PCSK9
|
RU2015106930A
(ru)
|
2012-09-06 |
2016-10-20 |
Новартис Аг |
Комбинированные вакцины с менингококком серогруппы в и к/д/с
|
EP4056198A3
(fr)
|
2012-09-18 |
2022-12-07 |
GlaxoSmithKline Biologicals SA |
Vésicules de membrane externe
|
EP2903650B1
(fr)
|
2012-10-02 |
2018-04-04 |
GlaxoSmithKline Biologicals SA |
Conjugués saccharidiques non linéaires
|
WO2014053612A1
(fr)
|
2012-10-03 |
2014-04-10 |
Novartis Ag |
Composition immunogène
|
JP6440619B2
(ja)
|
2012-10-12 |
2018-12-19 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
混合ワクチン用の架橋されていない無細胞百日咳抗原
|
ES2826555T3
(es)
|
2012-11-30 |
2021-05-18 |
Glaxosmithkline Biologicals Sa |
Antígenos de Pseudomonas y combinación de antígenos
|
JP6290918B2
(ja)
|
2012-12-05 |
2018-03-07 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
TW201502136A
(zh)
|
2013-03-15 |
2015-01-16 |
Glaxosmithkline Biolog Sa |
疫苗
|
EA032326B1
(ru)
|
2013-04-18 |
2019-05-31 |
Иммьюн Дизайн Корп. |
Монотерапия gla для применения в лечении рака
|
US20210145963A9
(en)
|
2013-05-15 |
2021-05-20 |
The Governors Of The University Of Alberta |
E1e2 hcv vaccines and methods of use
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
GB201310008D0
(en)
|
2013-06-05 |
2013-07-17 |
Glaxosmithkline Biolog Sa |
Immunogenic composition for use in therapy
|
EP3492097A1
(fr)
|
2013-08-05 |
2019-06-05 |
GlaxoSmithKline Biologicals S.A. |
Compositions immunogènes en combinaison
|
US10392603B2
(en)
|
2013-08-30 |
2019-08-27 |
The Chemo-Sero-Therapeutic Research Institute |
Method of viral purification
|
WO2015063611A2
(fr)
|
2013-11-01 |
2015-05-07 |
University Of Oslo |
Variants d'albumine et utilisations de ceux-ci
|
EP2870974A1
(fr)
|
2013-11-08 |
2015-05-13 |
Novartis AG |
Vaccins conjugués de salmonelle
|
DK3069138T3
(en)
|
2013-11-15 |
2019-04-08 |
Univ Oslo Hf |
CTL PEPTID EPITOPES AND ANTIGEN-SPECIFIC T-CELLS, METHODS OF RECOGNITION THEREOF, AND APPLICATIONS THEREOF
|
WO2015092710A1
(fr)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Administration simultanée controlatérale de vaccins
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
NZ759686A
(en)
|
2014-01-21 |
2023-07-28 |
Pfizer |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2015123291A1
(fr)
|
2014-02-11 |
2015-08-20 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Vaccin à base de pcsk9 et méthodes d'utilisation dudit vaccin
|
TW201620927A
(zh)
|
2014-02-24 |
2016-06-16 |
葛蘭素史密斯克藍生物品公司 |
Uspa2蛋白質構築體及其用途
|
MX2016012166A
(es)
*
|
2014-03-25 |
2017-03-15 |
The Government Of The Us Secretary Of The Army |
Metodos para mejorar la potencia de inmunoestimulacion de vacunas adsorbidas con sales de aluminio.
|
BR112016022011A2
(pt)
|
2014-03-26 |
2017-10-24 |
Glaxosmithkline Biologicals Sa |
?antígeno de proteína estafilocócica a mutante, proteína de fusão, e, composição imunogênica?
|
MX2016016533A
(es)
|
2014-06-13 |
2017-05-01 |
Glaxosmithkline Biologicals Sa |
Combinaciones inmunogenas.
|
MX2016017094A
(es)
|
2014-06-25 |
2017-05-03 |
Glaxosmithkline Biologicals Sa |
Composicion inmunógena de clostridium difficile.
|
WO2016011386A1
(fr)
|
2014-07-18 |
2016-01-21 |
University Of Washington |
Compositions de vaccin anticancéreux et leurs méthodes d'utilisation
|
WO2016012385A1
(fr)
|
2014-07-21 |
2016-01-28 |
Sanofi Pasteur |
Composition de vaccin comprenant du pvi et des cyclodextrines
|
CN106715464B
(zh)
|
2014-07-23 |
2021-03-16 |
奥克兰儿童医院及研究中心 |
因子h结合蛋白变体及其使用方法
|
JP7158853B2
(ja)
|
2014-10-10 |
2022-10-24 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
対象における食物アレルギーまたは呼吸器アレルギーを処置するための、かつ上記対象の鼻腔内に投与するための免疫原性組成物
|
AU2015252119A1
(en)
|
2014-11-07 |
2016-05-26 |
Takeda Vaccines, Inc. |
Hand, foot, and mouth vaccines and methods of manufacture and use thereof
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
AU2015359503B2
(en)
|
2014-12-10 |
2019-05-09 |
Glaxosmithkline Biologicals Sa |
Method of treatment
|
KR102149760B1
(ko)
|
2015-01-15 |
2020-08-31 |
화이자 인코포레이티드 |
폐렴구균 백신에서 사용하기 위한 면역원성 조성물
|
WO2016141320A2
(fr)
|
2015-03-05 |
2016-09-09 |
Northwestern University |
Virus non neuro-invasifs et leurs utilisations
|
US20180071380A1
(en)
|
2015-03-20 |
2018-03-15 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
JP2018521016A
(ja)
|
2015-06-03 |
2018-08-02 |
アフィリス・アクチェンゲゼルシャフトAffiris Ag |
IL−23−p19ワクチン
|
AU2016281904B2
(en)
|
2015-06-26 |
2022-08-11 |
Seqirus UK Limited |
Antigenically matched influenza vaccines
|
CA2991544A1
(fr)
|
2015-07-07 |
2017-01-12 |
Affiris Ag |
Vaccins pour le traitement et la prevention de maladies mediees par ige
|
TWI756893B
(zh)
|
2015-07-21 |
2022-03-01 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201518668D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Immunogenic Comosition
|
US10786561B2
(en)
|
2015-11-20 |
2020-09-29 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
BE1024160B9
(fr)
|
2015-12-22 |
2017-12-06 |
Glaxosmithkline Biologicals Sa |
Formulation immunogène
|
TN2018000301A1
(en)
|
2016-03-14 |
2020-01-16 |
Univ Oslo |
Engineered immunoglobulins with altered fcrn binding
|
WO2017158421A1
(fr)
|
2016-03-14 |
2017-09-21 |
University Of Oslo |
Immunoglobulines anti-virales synthétiques
|
US11173207B2
(en)
|
2016-05-19 |
2021-11-16 |
The Regents Of The University Of Michigan |
Adjuvant compositions
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
WO2017221072A2
(fr)
|
2016-06-21 |
2017-12-28 |
University Of Oslo |
Fragments de vaccin de liaison à hla et leurs utilisations
|
WO2018037045A1
(fr)
|
2016-08-23 |
2018-03-01 |
Glaxosmithkline Biologicals Sa |
Peptides de fusion avec des antigènes liés à des fragments courts de chaîne invariante (cd74)
|
GB201614799D0
(en)
|
2016-09-01 |
2016-10-19 |
Glaxosmithkline Biologicals Sa |
Compositions
|
BE1024774B1
(fr)
|
2016-09-29 |
2018-07-02 |
Glaxosmithkline Biologicals Sa |
Compositions et procedes de traitement
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
WO2018096396A1
(fr)
|
2016-11-22 |
2018-05-31 |
University Of Oslo |
Variants d'albumine et leurs utilisations
|
EP3551222A1
(fr)
|
2016-12-07 |
2019-10-16 |
GlaxoSmithKline Biologicals SA |
Nouveau procédé
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
MX2019006349A
(es)
|
2016-12-16 |
2019-08-22 |
Inst Res Biomedicine |
Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas.
|
GB201621686D0
(en)
|
2016-12-20 |
2017-02-01 |
Glaxosmithkline Biologicals Sa |
Novel methods for inducing an immune response
|
EP3570879B1
(fr)
|
2017-01-20 |
2022-03-30 |
Pfizer Inc. |
Composition immunogène pour l'utilisation dans vaccin pneumococcique
|
WO2018178265A1
(fr)
|
2017-03-31 |
2018-10-04 |
Glaxosmithkline Intellectual Property Development Limited |
Composition immunogène, utilisation et procédé de traitement
|
BR112019020209A2
(pt)
|
2017-03-31 |
2020-06-02 |
Glaxosmithkline Intellectual Property Development Limited |
Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação.
|
SG11201909265QA
(en)
|
2017-04-19 |
2019-11-28 |
Inst Res Biomedicine |
Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
|
WO2018198085A1
(fr)
|
2017-04-28 |
2018-11-01 |
Glaxosmithkline Biologicals Sa |
Vaccination
|
GB201707700D0
(en)
|
2017-05-12 |
2017-06-28 |
Glaxosmithkline Biologicals Sa |
Dried composition
|
BR112019025193A2
(pt)
|
2017-05-30 |
2020-06-23 |
Glaxosmithkline Biologicals S.A. |
Métodos de fabricação de um adjuvante lipossomal, de fabricação de um concentrado lipossomal, para a preparação de uma composição imunogênica com adjuvante e para a preparação de uma solução, adjuvante lipossomal, composição imunogênica com adjuvante, e, solução
|
US11723966B2
(en)
|
2017-08-14 |
2023-08-15 |
Glaxosmithkline Biologicals Sa |
Methods of boosting immune responses
|
EP3678699A1
(fr)
|
2017-09-07 |
2020-07-15 |
University Of Oslo |
Molécules vaccinales
|
US20220118076A1
(en)
|
2017-09-07 |
2022-04-21 |
University Of Oslo |
Vaccine molecules
|
US20200276299A1
(en)
|
2017-09-08 |
2020-09-03 |
Infectious Disease Research Institute |
Liposomal formulations comprising saponin and methods of use
|
SG11202003800YA
(en)
|
2017-11-03 |
2020-05-28 |
Takeda Vaccines Inc |
Zika vaccines and immunogenic compositions, and methods of using the same
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
MX2020013553A
(es)
|
2018-06-12 |
2021-02-26 |
Glaxosmithkline Biologicals Sa |
Polinucleotidos y polipeptidos de adenovirus.
|
EP3581201A1
(fr)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 polypeptides et leurs utilisations
|
CN110680909A
(zh)
*
|
2018-07-04 |
2020-01-14 |
辽宁成大生物股份有限公司 |
一种速释b型流感嗜血杆菌结合疫苗可溶性微针贴及其制备方法
|
US20210292395A1
(en)
|
2018-07-31 |
2021-09-23 |
Glaxosmithkline Biologicals Sa |
Antigen purification method
|
MX2021001479A
(es)
|
2018-08-07 |
2021-04-28 |
Glaxosmithkline Biologicals Sa |
Novedosos procesos y vacunas.
|
JP2021534761A
(ja)
|
2018-08-23 |
2021-12-16 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性タンパク質および組成物
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
US20220000779A1
(en)
|
2018-12-06 |
2022-01-06 |
Glaxosmithkline Biologicals Sa |
Immunogenic compositions
|
US20220016229A1
(en)
|
2018-12-12 |
2022-01-20 |
Pfizer Inc. |
Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
|
WO2020128012A1
(fr)
|
2018-12-21 |
2020-06-25 |
Glaxosmithkline Biologicals Sa |
Méthodes d'induction d'une réponse immunitaire
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
TW202102256A
(zh)
|
2019-03-05 |
2021-01-16 |
比利時商葛蘭素史密斯克藍生物品公司 |
B型肝炎免疫法及組合物
|
CA3136278A1
(fr)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Compositions immunogenes comprenant des antigenes saccharidiques capsulaires conjugues, kits les comprenant et leurs utilisations
|
US20220221455A1
(en)
|
2019-04-18 |
2022-07-14 |
Glaxosmithkline Biologicals Sa |
Antigen binding proteins and assays
|
EP3770269A1
(fr)
|
2019-07-23 |
2021-01-27 |
GlaxoSmithKline Biologicals S.A. |
Quantification de glycosylation de bioconjugués
|
WO2021014385A1
(fr)
|
2019-07-24 |
2021-01-28 |
Glaxosmithkline Biologicals Sa |
Protéines de cytomégalovirus humain modifiées
|
BR112021026565A2
(pt)
|
2019-08-05 |
2022-05-03 |
Glaxosmithkline Biologicals Sa |
Composição imunogênica
|
EP4009951A1
(fr)
|
2019-08-05 |
2022-06-15 |
GlaxoSmithKline Biologicals S.A. |
Procédé de préparation d'une composition comprenant un polypeptide de protéine d
|
EP3777884A1
(fr)
|
2019-08-15 |
2021-02-17 |
GlaxoSmithKline Biologicals S.A. |
Composition immunogène
|
CN114466659A
(zh)
|
2019-09-09 |
2022-05-10 |
葛兰素史克生物有限公司 |
免疫治疗组合物
|
WO2021084429A1
(fr)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Compositions d'escherichia coli et méthodes associées
|
WO2021122551A1
(fr)
|
2019-12-19 |
2021-06-24 |
Glaxosmithkline Biologicals Sa |
Antigènes de s. aureus et compositions associées
|
AU2021211012A1
(en)
|
2020-01-24 |
2022-08-25 |
Aim Immunotech Inc. |
Methods, compositions, and vaccines for treating a virus infection
|
US20230109142A1
(en)
|
2020-02-14 |
2023-04-06 |
Immunor As |
Corona virus vaccine
|
CN115362177A
(zh)
|
2020-02-21 |
2022-11-18 |
辉瑞公司 |
糖类的纯化
|
JP2023514697A
(ja)
|
2020-02-23 |
2023-04-07 |
ファイザー・インク |
大腸菌組成物およびその方法
|
MX2022013855A
(es)
|
2020-05-05 |
2022-11-30 |
Glaxosmithkline Biologicals Sa |
Dispositivos de mezcla de microfluidos y metodos de uso.
|
US20230293659A1
(en)
|
2020-08-03 |
2023-09-21 |
Glaxosmithkline Biologicals Sa |
Truncated fusobacterium nucleatum fusobacterium adhesin a (fada) protein and immunogenic compositions thereof
|
KR20230096033A
(ko)
|
2020-10-27 |
2023-06-29 |
화이자 인코포레이티드 |
에스케리키아 콜라이 조성물 및 그의 방법
|
CN116744965A
(zh)
|
2020-11-04 |
2023-09-12 |
辉瑞大药厂 |
用于肺炎球菌疫苗的免疫原性组合物
|
EP4243863A2
(fr)
|
2020-11-10 |
2023-09-20 |
Pfizer Inc. |
Compositions immunogènes comprenant des antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
MX2023006320A
(es)
|
2020-12-02 |
2023-06-14 |
Glaxosmithkline Biologicals Sa |
Cadena donante complementada fimh.
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
WO2022147373A1
(fr)
|
2020-12-31 |
2022-07-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Immunogènes imitant la pcsk9 guidés par des anticorps et ne présentant pas de chevauchement de séquence de 9 résidus avec des protéines humaines
|
US20220226465A1
(en)
|
2021-01-18 |
2022-07-21 |
ConserV Bioscience |
Coronavirus Immunogenic Compositions, Methods and Uses Thereof
|
CA3210363A1
(fr)
|
2021-02-11 |
2022-08-18 |
Glaxosmithkline Biologicals Sa |
Fabrication de vaccin contre le vph
|
JP2024507828A
(ja)
|
2021-02-19 |
2024-02-21 |
サノフィ パスツール インコーポレイテッド |
B群髄膜炎菌組換えワクチン
|
JP2024510717A
(ja)
|
2021-02-22 |
2024-03-11 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物、使用及び方法
|
TW202305125A
(zh)
|
2021-04-30 |
2023-02-01 |
美商凱立凡爾免疫治療股份有限公司 |
用於經修飾mhc表現之溶瘤病毒
|
TW202306969A
(zh)
|
2021-05-28 |
2023-02-16 |
美商輝瑞大藥廠 |
包含結合之莢膜醣抗原的免疫原組合物及其用途
|
AU2022281543A1
(en)
|
2021-05-28 |
2023-11-23 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023020994A1
(fr)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Nouveaux procédés
|
WO2023020993A1
(fr)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Nouveaux procédés
|
WO2023020992A1
(fr)
|
2021-08-16 |
2023-02-23 |
Glaxosmithkline Biologicals Sa |
Nouveaux procédés
|
WO2023092090A1
(fr)
|
2021-11-18 |
2023-05-25 |
Matrivax, Inc. |
Compositions de protéines de fusion immunogènes et leurs procédés d'utilisation
|
WO2023135515A1
(fr)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Compositions immunogènes à base d'antigènes saccharidiques capsulaires conjugués et leurs utilisations
|
WO2023144665A1
(fr)
|
2022-01-28 |
2023-08-03 |
Glaxosmithkline Biologicals Sa |
Protéines de cytomégalovirus humain modifiées
|
WO2023161817A1
(fr)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Procédés d'incorporation de groupes azido dans des polysaccharides capsulaires bactériens
|
WO2023218322A1
(fr)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Procédé de production de formulations de vaccin avec des conservateurs
|